Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have strong conviction about the potential clinical impact of RMC-6236 and serving the real unmet needs in lung cancer and with continuing consultation with advisers and engaging as appropriate with regulators, in 2024, we expect to initiate a pivotal Phase 3 monotherapy second-line non-small cell lung cancer trial focused on achieving full regulatory approval and with a potential accelerated approval opportunity built in via an interim analysis |
| For all of these reasons, our expert advisers, and we believe that RMC-6236 is performing well by this standard for patients who are facing grim prospects with standard of care |
| There's no doubt, but I think it will increase our productivity and maximize value creation |
| And secondly, the relative positive guidance coming from the FDA about the specific requirements for -- to fulfill the Project Optimus initiative |
| We believe Revolution Medicines has an unprecedented opportunity to deliver high-impact benefit to patients through our pipeline |
| We have heard broad and strong support for the Rev Med portfolio approach and proposed transaction |
| In aggregate, these findings are highly encouraging and point to large opportunities ahead for these first two compounds |
| And toward that goal, the deal with EQRx will markedly enhance our ability to bring the most out of these exciting compounds |
| But here, there are also encouraging signs |
| This differentiating feature of RMC-6236 is a core lever for evaluating meaningful clinical benefit |
| Our strengthened balance sheet is intended to enable the larger investments needed to support the parallel data-driven, late-stage development for our RAS(ON) inhibitor pipeline focused initially on RMC-6236, 6291 and 980 |
| We are likewise excited about the potential for RMC-6236 in pancreatic cancer, where unmet needs are certainly profound |
| These observations with the first-ever RASMULTI inhibitor in the clinic, our dogma breaking and demonstrate clearly that this compound has a very sound therapeutic window |
| First, objectively and by hands-on investigator experience treating over 131 patients so far, RMC-6236 is well tolerated at clinically active doses, including 300 milligrams QD as reported to us by investigators |
| First, objectively and by investigators who have treated more than 63 patients so far, RMC-6291, is well tolerated across a wide range of clinically active doses, and so far, investigators report that it is well tolerated |
| The employees of Revolution Medicines renew our deep commitment to out smart cancer on behalf of patients and to build share value for our investors |
| Just philosophically, since the safety profile looks really good |
| This differentiation is highly encouraging for the potential of RMC-6291 itself as a drug, and it supports our preclinical prediction that inhibition of the RAS(ON) state in a human tumor may be biologically differentiated relative to inhibition of the RAS(OFF) state |
| These are highly encouraging findings |
| The blended objective response rate in non-small cell lung cancer is already solid at 38% in the data we shared in October |
| Second, good tolerability enables continuity of treatment and patients receiving RMC-6291 have required a few dose interruptions and even fewer discontinuations for intolerability |
| While these objective response rate observations are encouraging, we continue to emphasize that objective response rate is not the key clinical endpoint for pancreatic ductal adenocarcinoma since rapid progression with short overall survival is the norm, even in those who respond initially to established treatments |
| Further, we believe this paradigm likely applies across our portfolio of RAS(ON) inhibitors boosting the probabilities of success across our entire deep pipeline |
| Expense ramp |
| Finally, we believe we have a proposed recommended Phase 2 dose for lung cancer in hand now, and expansions are underway to develop a robust data set we think is needed to satisfy project Optimus |
| Second, this profile is enabling continuity of dosing, which we believe is critical in treating RAS-addicted cancers |
| We appreciate your continued support of Revolution Medicines |
| The disease control rate we shared in October was 87% and significantly higher than most reports for salvage chemotherapy in pancreatic cancer |
| Next, I'd like to comment on our exciting second investigational drug to show clinical activity, RMC-6291 for KRAS G12C cancers and try to paint the picture we see based on the recent update and extensive dialogue with investigators and clinical experts |
| In the context of third-line or later, the reported objective response rate has been zero to 4%, while the response rate for such patients in our study was at higher-higher than the overall 20% number |
| Statement |
|---|
| And often, drugs that look pretty promising, have struggled a bit to or even failed to beat just the tax |
| And frankly, that's when the scans are done, and there's a very dramatic drop-off in freedom from progression at the point at which that second scan is done |
| Mark Goldsmith And if I could add to that on that last point, what Steve's alluding to is sort of regardless of our confidence in the activity against G12C, there still are operational issues associated with having approved G2C inhibitors available and dozens of G12C inhibitors, G12C(OFF) inhibitors in clinical studies |
| GAAP net loss for the third quarter of 2023 was $108.4 million or $0.99 per share |
Please consider a small donation if you think this website provides you with relevant information